Quarterly ResultJul 29, 2026, 04:14 PM
Anika Therapeutics Returns to Profit in Q2 2026; Revenue Up 15.6%
AI Summary
Anika Therapeutics, Inc. reported a return to net income in the second quarter of 2026, achieving $3.31 million compared to a net loss of $3.97 million in the prior year. Revenue increased by 15.6% to $32.61 million for the quarter. Year-to-date, the company significantly reduced its net loss to $1.75 million from $8.84 million in the first half of 2025. Additionally, stockholders approved amendments to equity incentive plans, increasing available shares for grants and employee stock purchases.
Key Highlights
- Q2 2026 Net Income: $3.31 million, up from a $3.97 million loss in Q2 2025.
- Q2 2026 Revenue: Increased 15.6% to $32.61 million from $28.22 million.
- YTD 2026 Net Loss: Reduced to $1.75 million from $8.84 million in YTD 2025.
- Q2 2026 Basic EPS: $0.25, compared to $(0.28) in Q2 2025.
- Stockholders approved increasing shares for 2017 Omnibus Incentive Plan by 350,000.
- Stockholders approved increasing shares for Employee Stock Purchase Plan by 200,000.
- YTD 2026 cash used in operating activities: $(5.53) million.
- YTD 2026 common stock repurchases: $9.54 million.
Price Impact
More from ANIK